Healthy volunteers help test copycat drug against approved biologic
NCT ID NCT07479576
First seen Mar 19, 2026 · Last updated Jun 16, 2026 · Updated 14 times
Summary
This study tests a new drug called QL2106 against an approved drug, Tremfye® (guselkumab), in 190 healthy adults aged 18-45. The goal is to compare how the body processes each drug, their safety, and immune response after a single dose. Participants receive one injection and are monitored for several months. This is a Phase 1 trial, so it focuses on safety and drug behavior, not on treating any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100000, China
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.